JPWO2021050203A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021050203A5
JPWO2021050203A5 JP2022516412A JP2022516412A JPWO2021050203A5 JP WO2021050203 A5 JPWO2021050203 A5 JP WO2021050203A5 JP 2022516412 A JP2022516412 A JP 2022516412A JP 2022516412 A JP2022516412 A JP 2022516412A JP WO2021050203 A5 JPWO2021050203 A5 JP WO2021050203A5
Authority
JP
Japan
Prior art keywords
cytisine
pharmaceutical composition
subject
vaping
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548876A5 (https=
JP2022548876A (ja
JP7742832B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046308 external-priority patent/WO2021050203A1/en
Publication of JP2022548876A publication Critical patent/JP2022548876A/ja
Publication of JP2022548876A5 publication Critical patent/JP2022548876A5/ja
Publication of JPWO2021050203A5 publication Critical patent/JPWO2021050203A5/ja
Priority to JP2025011057A priority Critical patent/JP2025081331A/ja
Application granted granted Critical
Publication of JP7742832B2 publication Critical patent/JP7742832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516412A 2019-09-12 2020-08-14 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物 Active JP7742832B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025011057A JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025011057A Division JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Publications (4)

Publication Number Publication Date
JP2022548876A JP2022548876A (ja) 2022-11-22
JP2022548876A5 JP2022548876A5 (https=) 2023-08-23
JPWO2021050203A5 true JPWO2021050203A5 (https=) 2023-08-23
JP7742832B2 JP7742832B2 (ja) 2025-09-22

Family

ID=74866435

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516412A Active JP7742832B2 (ja) 2019-09-12 2020-08-14 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
JP2025011057A Pending JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025011057A Pending JP2025081331A (ja) 2019-09-12 2025-01-27 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119587493A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
WO2024226736A2 (en) * 2023-04-26 2024-10-31 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125699B (en) 1982-02-22 1986-02-12 Bruss Ni Sanitarno Gigieniches Medicinal preparation having antinicotine effect and method for obtention thereof
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN104906669A (zh) * 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JP6324964B2 (ja) 2013-08-23 2018-05-16 久光製薬株式会社 貼付剤
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
EP3658561A1 (en) * 2017-07-24 2020-06-03 Achieve Pharma UK Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Similar Documents

Publication Publication Date Title
Perri et al. Treatment of Helicobacter pylori infection
JP2024074963A5 (https=)
JP2025081331A5 (https=)
JP2018507243A5 (https=)
JP2006513184A5 (https=)
Ventafridda et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs
Kosugi et al. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
US20050100513A1 (en) Homeopathic method and system for treating nicotine addiction
US9061052B2 (en) Aqueous extract of tobacco leaves, its uses in the treatment of dependence
JP2016505050A5 (https=)
JPWO2021050203A5 (https=)
JP2021521103A5 (https=)
Engelsman et al. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study.
Bolliger et al. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy
Agrawal et al. Medical management of inpatients with tobacco dependency
RU2495682C1 (ru) Способ доставки лекарственного средства при лечении или профилактике табакокурения и/или заболеваний органов дыхания
CA2506962A1 (en) Synergistic combination comprising roflumilast and formoterol
JPWO2023186829A5 (https=)
Yagoubian et al. Nicotine nasal spray as an adjuvant analgesic for third molar surgery
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
JPWO2023186832A5 (https=)
Jorenby et al. Comparative efficacy and tolerability of nicotine replacement therapies
JP2006508993A5 (https=)
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法